The drug development process in psychiatry faces significant challenges due to low reproducibility rates in animal testing, which often leads to translation failures. To address this issue, we introduce a new approach in psychiatric drug development: a preclinical randomized controlled trial (preRCT). To demonstrate its potential utility, we conducted a multi-center preRCT using the alcohol deprivation effect (ADE) model to assess the impact of ketamine and R-ketamine on alcohol relapse across three European research centers. Ketamine (20 mg/kg) significantly reduced relapse, while R-ketamine showed efficacy only in females. A higher dose of R-ketamine (40 mg/kg) was also effective in males. These sex-dependent effects were linked to plasma R-ketamine levels, which were two-fold higher in female compared to male rats. Notably, R-ketamine demonstrated a lasting reduction in alcohol consumption without adverse effects. In conclusion, our preRCT demonstrates R-ketamine's effectiveness in reducing alcohol relapse and supports translation to a clinical RCT that accounts for sex-dependent effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41386-025-02071-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions.
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFT-cell Engagers in Prostate Cancer.
Eur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFBispecific antibody therapy for lymphoma.
Best Pract Res Clin Haematol
December 2024
330 Brookline Ave, Boston, MA, 02215, USA. Electronic address:
The rapid development of novel therapeutics in B-cell Non-Hodgkin's lymphoma (B-NHL) over the past decade has presented a critical inflection point for the field. Bispecific antibodies are one such therapeutic class emerging as an effective, off-the-shelf option for B-NHL. In this review, we focus primarily on Diffuse Large B-cell Lymphoma (DLBCL), highlighting the evolution, comparison, tolerability, ongoing challenges, and future potential of bispecific antibodies that are currently approved or in clinical trials for B-NHL.
View Article and Find Full Text PDFAssociation Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm.
J Am Coll Cardiol
March 2025
Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins Medicine, Baltimore, Maryland, USA; American Heart Association Tobacco Regulation and Addiction Center, Dallas, Texas, USA. Electronic address:
Background: Cigarette smoking is a strong risk factor for cardiovascular harm.
Objectives: The study sought to explore the detailed relationships between smoking intensity, pack-years, and time since cessation with inflammation, thrombosis, and subclinical atherosclerosis markers of cardiovascular harm.
Methods: We included 182,364 participants (mean age 58.
Comprehensive evaluation of antibacterial and anticancer activities from indole butanoic acid.
J Genet Eng Biotechnol
March 2025
Department of Chemistry, College of Sciences, Jouf University, PO Box 72341, Sakaka, Saudi Arabia.
Focus of this study is on the use of the hydrazone compound (3) (N-(4-bromobenzylidene)-4-(1H-indol-3-yl) butane hydrazide), which was previously prepared from the reaction of the compound p-bromobenzaldehyde with the corresponding hydrazide (2), as an intermediate compound for the synthesis of azetidine, thiazolidine, tetrazole, oxadiazole and phthalazine heterocyclic compounds through its reaction with some cyclic reagents and catalysts such as chloro acetyl chloride, thioglycolic acid, sodium-azid, lead dioxide and Hydrogen chloride gas. The prepared compounds were characterized using physical properties and also spectroscopic methods such as infrared spectroscopy, nuclear magnetic resonance spectra of the proton and the isotope of carbon as well as mass spectrometry, which accurately identified the proposed structures of the prepared compounds. The identity of the prepared compounds was determined using physical and spectroscopic properties, where infrared and HNMR spectroscopy of the proton as well as carbon were used in addition to using mass spectrometry to verify the validity of the prepared structures.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!